MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

MariTide's development in obesity treatment is crucial, but concerns about its progress and competition from Novo and Lilly remain. Despite strong performance, Amgen's high debt levels and ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key ...